Committed to providing accessible screening and diagnostic testing solutions and services that identify patients at risk for rare but treatable genetic disorders

We aim to save lives and relieve the burden of disease for patients and their families afflicted by rare treatable genetic disorders through early screening. Through our rapid and scalable pioneering proteomic technology, we empower early intervention to alter the clinical trajectory, starting with newborns today and paving the way for applications across diverse patient populations tomorrow.

NO TREATABLE GENETIC DISORDER SHOULD GO UNSEEN

Many people with treatable genetic disorders may not have symptoms until later in childhood or early adulthood. If left undiagnosed, these disorders can have irreversible or fatal outcomes. Key Proteo’s pioneering Immuno-SRM proteomic technology reveals previously undetectable disorders to help advance newborn screening programs.

72%

70%

OF 6000+ KNOWN RARE DISEASES ARE GENETIC¹

$266K

AVERAGE ECONOMIC BURDEN PER PATIENT, PER YEAR²

4-5 YEARS

AVERAGE TIME OF DIAGNOSIS OF A RARE DISEASE³

OF RARE GENETIC DISEASES MANIFEST IN CHILDHOOD¹

KEY PROTEO IS ADDRESSING A CRITICAL UNMET NEED

Key Proteo is addressing this critical unmet need with our novel Immuno-SRM technology. Through our rapid and scalable pioneering protemic technology, we are empowering early intervention for life-changing outcomes.

OUR SOLUTION: IMMUNO-SRM TECHNOLOGY

ACCURATE DETECTION

Our novel Immuno-SRM proteomic-based screening platform detects extremely low-abundance proteins.
NECESSARY SCREENING

Early identification of previously undetectable genetic disorders can help avoid the burdensome diagnostic odyssey before symptoms manifest.
SCALABLE WORKFLOW

A rapid, scalable, and cost-effective solution - easy to implement with familiar workflows.